Article Versions Notes

Chen L, Liao W, Huang J, Ding Q, Wu J, Zhang Q, Ding Y, Li D, Li J, Wen X, et al. Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma. Pharmaceuticals. 2025; 18(5):666. https://doi.org/10.3390/ph18050666

Chen, Linbin, Wanqian Liao, Jing Huang, Qiuyue Ding, Junwan Wu, Qiong Zhang, Ya Ding, Dandan Li, Jingjing Li, Xizhi Wen, and et al. 2025. "Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma" Pharmaceuticals 18, no. 5: 666. https://doi.org/10.3390/ph18050666

Chen, L., Liao, W., Huang, J., Ding, Q., Wu, J., Zhang, Q., Ding, Y., Li, D., Li, J., Wen, X., & Zhang, X. (2025). Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma. Pharmaceuticals, 18(5), 666. https://doi.org/10.3390/ph18050666